TRCT
MLTX icon

Tower Research Capital (TRC)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.5K Buy
+2,952
New +$53.5K ﹤0.01% 2625
2026
Q1 		– Sell
-704
Closed -$9.28K – 5386
2025
Q4 		$9.28K Buy
704
+703
+70,300% +$8.29K ﹤0.01% 3909
2025
Q3 		$7 Sell
1
-273
-100% -$14.2K ﹤0.01% 5182
2025
Q2 		$12.9K Buy
274
+128
+88% +$5.21K ﹤0.01% 3880
2025
Q1 		$5.7K Buy
+146
New +$6.29K ﹤0.01% 4093
2024
Q4 		– Sell
-1,672
Closed -$84.3K – 5885
2024
Q3 		$84.3K Buy
1,672
+1,625
+3,457% +$76.1K ﹤0.01% 2353
2024
Q2 		$2.07K Sell
47
-232
-83% -$9.83K ﹤0.01% 5057
2024
Q1 		$14K Buy
279
+214
+329% +$11.6K ﹤0.01% 3346
2023
Q4 		$3.92K Sell
65
-127
-66% -$6.54K ﹤0.01% 5025
2023
Q3 		$10.9K Sell
192
-720
-79% -$39.7K ﹤0.01% 4058
2023
Q2 		$46.5K Buy
+912
New +$24.5K ﹤0.01% 2644
2022
Q3 		– Sell
-25
Closed – – 6323
2022
Q2 		$0 Buy
+25
New +$157 ﹤0.01% 6353
2022
Q1 		– Sell
-193
Closed -$2K – 6376
2021
Q4 		$2K Buy
193
+76
+65% +$755 ﹤0.01% 5638
2021
Q3 		$1K Buy
117
+100
+588% +$998 ﹤0.01% 5503
2021
Q2 		$0 Buy
+17
New +$173 ﹤0.01% 5696
2021
Q1 		– Sell
-7
Closed – – 5586
2020
Q4 		$0 Buy
+7
New +$74 ﹤0.01% 5307

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tower Research Capital (TRC)'s MLTX Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 2,952 shares worth $57.5K. The stake represents ﹤0.01% of the portfolio and ranks #2625 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in MLTX as recently as Q4 2025.

Tower Research Capital (TRC) first reported a position in MLTX in Q4 2020 and has held it in 16 quarters since. The position peaked at $84.3K in Q3 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Tower Research Capital (TRC) held 2,952 shares of MoonLake Immunotherapeutics worth $57.5K as of Q2 2026.
  • MoonLake Immunotherapeutics was a new Tower Research Capital (TRC) position in Q2 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2625 holding.
  • Tower Research Capital (TRC) first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 16 quarters since.
  • Tower Research Capital (TRC)'s MoonLake Immunotherapeutics position peaked at $84.3K in Q3 2024.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.